Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene

Beatriz Mendes Awni a  Carlos Diego Holanda Lopes a 
Guilherme Harada a  Alessandra Corte Real Salgues a 
Gilmar de Andrade França a  Leonardo de Abreu Testagrossa a 
Marcelo Araujo Queiroz a, b  Adriano Gonçalves e Silva c 
Fabio de Oliveira Ferreira b  Rodrigo Ramella Munhoz a, b

aOncology Center, Hospital Sírio-Libanês (HSL), São Paulo, Brazil; bCutaneous Malignancies and Sarcomas Group, Hospital Sírio Libanês, São Paulo, Brazil; cCancer and Transplant Institute, Curitiba, Brazil

Keywords
Werner’s syndrome · WRN · Liposarcoma · Hematological and renal toxicities

Abstract
Werner’s syndrome is caused by the inactivation of both WRN alleles and is characterized by premature aging and increased risk of neoplasms, especially those of mesenchymal origins, such as sarcomas. Given the characteristic genomic instability, patients with this syndrome are more susceptible to develop toxicities when exposed to cytotoxic agents, such as alkylators and anthracyclines. The impact of the monoallelic WRN mutation on treatment-associated toxicities is poorly understood. Here, we report a patient with locally advanced dedifferentiated liposarcoma of the retroperitoneum harboring a heterozygous germline inactivation mutation in the WRN gene, who was treated with a classic regimen of ifosfamide and doxorubicin and developed exacerbated and prolonged hematological and renal toxicities.
Introduction

The WRN gene codes one of the five RecQ DNA helicase proteins and displays important functions in DNA replication and repair, as well as in the maintenance of telomeres and transcriptional modulation, through different DNA metabolic pathways [1]. Inactivation of both WRN alleles originates the Werner syndrome (WS), a rare autosomal recessive disease, characterized by premature aging and increased risk of various neoplasms, predominantly of mesenchymal origin, sarcomas being one of the most prevalent [2]. An overall incidence rate of less than 1 in 100,000 live births per year is estimated. Because of characteristically genomic instability, patients with WRN mutations may develop enhanced toxicities when exposed to cytotoxic agents, markedly alkylators and anthracyclines, such as ifosfamide and doxorubicin, which are frequently included in treatment regimens for patients with soft tissue sarcomas [3, 4]. Nevertheless, the impact of heterozygous WRN mutation on treatment-associated toxicities is uncertain. Here, we describe a case of a patient harboring a WRN mutation in heterozygosis with a locally advanced retroperitoneal dedifferentiated liposarcoma who developed exacerbated and prolonged hematological and renal toxicities after ifosfamide and doxorubicin exposure.

Case Report

A 60-year-old man with no comorbidities was diagnosed with a retroperitoneal soft tissue mass, measuring 12 × 12 × 9 cm by magnetic resonance imaging, in July 2020. The lesion biopsy was compatible with high-grade liposarcoma, and IHC stained positive for MDM2 and CDK4. From July 2020, he received systemic treatment with doxorubicin 25 mg/m² and ifosfamide 3 g/m² on days 1–3 for four cycles. Throughout the systemic treatment performed at an outside facility, he required repeated transfusions of red blood cells due to grade 3 anemia and developed moderate to severe neutropenia. Myelotoxicity was accompanied by progressive worsening of renal function (Table 1). However, chemotherapy (CTx) dose adjustment was unnecessary because of a sustained creatinine clearance greater than 60 mL/min/1.73 m² by Chronic Kidney Disease Epidemiology Collaboration. Restaging scans following cycle #4 revealed a significant reduction in tumor size (Fig. 1), allowing for potential complete salvage surgery. Following the completion of CTx, the decision was made to proceed with neoadjuvant radiation therapy, performed to a total dose of 42 Gy, delivered in 15 fractions. The patient then transitioned his care for surgical resection. Laboratory workup upon admission revealed both persistent myelotoxicity and renal insufficiency (creatinine clearance upon admission: 17 mL/min/1.73 m² by Chronic Kidney Disease Epidemiology Collaboration), despite an interval of 3 months since the last CTx cycle. Viral etiologies and nutritional deficiencies were ruled out. A myelogram was performed and showed normocellular bone marrow, with a maturation delay in the neutrophilic sector; a bone marrow biopsy showed no signs of malignancy. Concerning renal insufficiency workup, urinalysis revealed non-nephrotic proteinuria (0.88 g/L) and glycosuria (7.78 g/L); assessment of immune-mediated glomerulopathies was negative, and no significant morphological or vascular changes affecting the kidneys were identified through additional imaging. The genomic profiling by the hybridization-based protocol for germline assessment (Invitae, San Francisco, CA, USA) revealed a pathogenic heterozygous mutation in WRN (c.3123C>A; p.Cys1041) and variants of uncertain significance in WRN (c.4018C>T; p.Pro1340Ser), EGFR (c.2963A>G; p.His988Arg), RAD50 (c.2468G>A; p.Arg823Gln), and RECQL4 (c.2176G>A; p.Ala726Thr). The patient gradually recovered his blood counts until late December 2020; however, the renal function deteriorated to levels demanding renal replacement therapy (Table 1). He ultimately underwent
surgical resection of the lesion in the retroperitoneum, whose pathological report indicated a high-grade DDLPS (Fig. 2), and a left renal biopsy showed karyomegalic tubulointerstitial nephropathy (Fig. 3). He started continuous hemodialysis in the immediate postoperative period and was discharged in good clinical conditions after 6 weeks.

**Discussion**

Here, we report a patient with locally advanced DDLPS of the retroperitoneum and heterozygous germline inactivation mutation in the WRN gene, treated with a classic regimen of ifosfamide and doxorubicin and developed significant renal and hematologic toxicity. In mammalians, RecQ helicases comprise a group of 5 proteins (RECQL1, BLM, WRN, RECQL4, and RECQL5) involved in critical cellular processes, highlighting those associated with genome integrity maintenance. By using ATP hydrolysis energy, RecQ helicases unwind double-strand DNA and re-modulate secondary DNA structures and DNA-protein complexes, allowing those other processes to be activated to repair genome insults, for example [5]. The critical function of these helicases is represented in inheritable conditions characterized by genomic instability, exacerbated tissue injury to some biological or chemical agent when one of five proteins is lost or difunctional (e.g., Bloom syndrome and WS) [6].

WS is one of the classic progeroid syndromes characterized by premature aging and increased risk of neoplasms, predominantly of mesenchymal origin, and sarcomas are most prevalent. This is a rare condition with a global incidence rate of less than 1 in 100,000 live births per year [2]. The pathogenesis consists of a WRN locus loss of function in chromosome 8p12 with a difunctional RecQ helicase correspondent protein, causing rapid replicative senescence, chromosomal instability, and sensitivity to various agents that damage DNA [7, 8].

### Table 1. Clinical laboratory results

| Date        | Hemoglobin, g/dL | Leukocytes, g/dL | Neutrophils, g/dL | Platelets, /mm3 | Creatinine, mg/dL | Urea, mg/dL |
|-------------|------------------|------------------|-------------------|-----------------|-------------------|-------------|
| 11 Apr 2019 | 14.8             | 6,060            | 4,266             | 200,000         | –                 | –           |
| 19 Jun 2020 | 10.4             | 10,380           | 7,370             | 353,000         | –                 | –           |
| 22 Jul 2020 | 9.3              | 650              | –                 | 166,000         | –                 | –           |
| 29 Aug 2020 | 10.1             | 9,810            | –                 | 303,000         | 0.96              | 30          |
| 9 Sep 2020  | 9.1              | 470              | –                 | 143,000         | –                 | –           |
| 19 Sep 2020 | 9.2              | 8,150            | 6,292             | 306,000         | 1.19              | 34          |
| 29 Sep 2020 | 8.8              | 240              | –                 | 172,000         | 1.89              | 40          |
| 9 Dec 2020  | 8.3              | 840              | 20                | 121,000         | –                 | –           |
| 10 Dec 2020 | 8.6              | 1,070            | 30                | 105,000         | 3.8               | 76          |
| 12 Dec 2020 | 8.0              | 1,100            | 40                | 115,000         | 3.98              | 88          |
| 15 Dec 2020 | 7.3              | 2,270            | 970               | 115,000         | 3.72              | 77          |
| 18 Dec 2020 | 7.8              | 5,690            | 4,450             | 107,000         | 4.27              | 83          |
| 24 Dec 2020 | 8.5              | 4,870            | 3,910             | 135,000         | 5.29              | 99          |
| 28 Dec 2020 | 9.1              | 2,910            | 2,140             | 153,000         | 6.02              | 103         |
| 11 Jan 2021 | 9.0              | 4,290            | 3,140             | 165,000         | 7.80              | 105         |
| 13 Jan 2021 | –                | –                | –                 | –               | 8.38              | 107         |

CTx, chemotherapy.
Despite the high incidence of sarcoma, there is little information regarding individualized treatment for patients with WS. Usually, a multimodal approach with anthracycline-based regimen CTx is the standard for localized soft tissue sarcomas [9]. In general, these drugs are well tolerated in cancer patients, but patients with mutations in the WRN gene may have more significant renal, neurological, cardiologic, and hematological toxicities [3, 4].

There are some reports of increased sensitivity of WS cells to the DNA damaged by cytotoxic CTx [10]. Moser et al. [11] used the glycoporphin A somatic cell mutation assay to analyze genetic instability in vivo in patients with WS and heterozygotes, showing that both are...
heterozygous and homozygous mutation in WRN which had an increased risk of neoplasia and toxicities related to CTx. It was the first and only evidence published in the literature of genetic instability in patients with a monoallelic mutation in WRN.

Damage to renal tubular cells in settle of both defective DNA repair and increased toxicity to nephrotoxic agents can cause severe and irreversible nephritis, such as karyomegalic interstitial nephritis (KIN) [12]. This renal pathology is a rare cause of chronic hereditary interstitial nephritis. Generally, it presents as a slowly progressive chronic kidney disease, leading to end-stage kidney disease in early adulthood [12, 13]. Although less common, ifosfamide-associated KIN has been described, mainly in young patients with a suggestion to recover renal function after a course of corticosteroids. Additionally, there is a direct association of mutations in Fanconi anemia-associated nuclease 1 (FAN1) as causing familiar KIN. As Fanconi anemia-associated nuclease 1 has endonuclease activity and is involved in DNA damage response in the Fanconi anemia pathway [14] and the RecQ helicases (like WRN) are involved in some of the primary mechanisms of DNA repair (base excision repair, nucleotide excision repair, and double-strand break repair) [15], we postulated that WRN mutation present in this patient exacerbated the sensibility of cells to DNA-damaged agents, ifosfamide (an alkylating agent) and doxorubicin (a topoisomerase two inhibitor) reflecting in high-grade hematologic and renal toxicities.

**Conclusion**

To the best of our knowledge, this is the first case described in the literature showing a patient with a heterozygous mutation in WRN with dramatic renal and hematological toxicity after cytotoxic CTx. It is noteworthy that, in these patients, close monitoring of hematologic profile and renal function should proceed, and individualization of the best therapeutic strategy is essential to avoid severe toxicities.

**Statement of Ethics**

This case report was approved by the Ethics Committee of the Hospital Sírio-Libanês, São Paulo, Brazil. Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

No funding was received for this study.

Author Contributions

All authors contributed equally to this manuscript conception and writing.

Data Availability Statement

The data are not publicly available due to their containing information that could compromise the privacy of research participant.

References

1 Lebel M, Monnat RJ. Werner syndrome (WRN) gene variants and their association with altered function and age-associated diseases. Ageing Res Rev. 2018 Jan;41:82–97.
2 Oshima J, Sidorova JM, Monnat RJ. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev. 2017 Jan;33:105–14.
3 Seiter K, Qureshi A, Liu D, Galvin-Parton P, Arshad M, Agoliati G, et al. Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner’s syndrome. Leuk Lymphoma. 2005 Jul;46(7):1091–5.
4 Tsukamoto S, Kurematsu Y, Honoki K, Kido A, Somekawa S, Kaya D, et al. Severe toxicity of chemotherapy against advanced soft tissue sarcoma in Werner’s syndrome: ifosfamide-induced encephalopathy with central diabetes insipidus. J Orthop Sci. 2016 May;21(3):403–6.
5 Bohr VA. Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance. Trends Biochem Sci. 2008 Dec;33(12):609–20.
6 Larsen NB, Hickson ID. RecQ helicases: conserved guardians of genomic integrity. Adv Exp Med Biol. 2013;767:161–84.
7 Yu C-E, Oshima J, Fu Y-H, Wijsman EM, Hisama F, Alisch R, et al. Positional cloning of the Werner’s syndrome gene. Science. 1996 Apr 12;272(5259):258–62.
8 Gray MD, Shen J-C, Kamath-Loeb AS, Blank A, Sopher BL, Martin GM, et al. The Werner syndrome protein is a DNA helicase. Nat Genet. 1997 Sep;17(1):100–3.
9 von Mehren M, Kane JM, Bui MM, Choy E, Connely M, Dry S, et al. NCCN guidelines in sights: soft tissue sarcoma, version 1.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2020 Dec;18(12):1604–12.
10 Seiter K, Liu D, Feldman E, Shi Q, Qureshi A, Arshad M, et al. Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma. 2006 Mar;47(3):425–32.